TRIOBP: A Potential Drug Target and Biomarker for F-Actin-Binding Proteins

Target Name: TRIOBP

NCBI ID: G11078

TRIOBP: A Potential Drug Target and Biomarker for F-Actin-Binding Proteins

Introduction

Proteins that can interact with various cell signaling pathways, including F-actin, play a crucial role in cellular processes such as cell adhesion, migration, and cytoskeletal organization. The protein TRIOBP (TRIO and F-actin-binding protein), is a member of the superfamily of actin-binding proteins known as the P1 complex. This protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Structure and Function

TRIOBP is a 21-kDa protein that contains a N-terminal region containing a unique heptadecapeptide repeat, a conserved motif that is also found in other actin-binding proteins. The C-terminus of TRIOBP contains a farnesylated cysteine 鈥嬧?媟esidue, which is important for protein stability and functions as an acceptor for the E3 ubiquitin transferase.

TRIOBP functions as an actin-binding protein by interacting with F-actin, which is a protein that plays a critical role in the cytoskeleton and is composed of two subunits, F1 and F2. The F1 subunit contains a long alpha-helices region that is involved in the formation of the actin filament, while the F2 subunit contains a short alpha-helices region that interacts with the terminal ends of the actin filaments.

TRIOBP has been shown to play a role in various cellular processes, including the regulation of cell adhesion, migration, and the development of neurodegenerative diseases. For example, TRIOBP has been shown to be involved in the regulation of tight junctions, which are a type of cell-cell adhesion that is critical for maintaining tissue structure and function.

In addition to its role in actin-binding, TRIOBP has also been shown to play a role in the regulation of cell survival and apoptosis. For example, TRIOBP has been shown to interact with the protein Bcl-2, which is a protein that plays a critical role in the regulation of cell apoptosis. This interaction between TRIOBP and Bcl-2 has been shown to contribute to the regulation of cell survival and the development of neurodegenerative diseases.

Drug Targeting

TRIOBP has been identified as a potential drug target due to its unique structure and function. The farnesylated cysteine 鈥嬧?媟esidue on the C-terminus of TRIOBP makes it a good candidate for inhibition with small molecules. Furthermore, the involvement of TRIOBP in various cellular processes, including cell adhesion, migration, and neurodegenerative diseases, making it an attractive target for drug development.

One of the most promising compounds that has been shown to interact with TRIOBP is the small molecule, KO-4223. KO-4223 is a inhibitor of the protein kinase kinase (PK) A, which is a critical enzyme involved in the regulation of cellular processes, including cell growth, apoptosis, and adhesion.

In preclinical studies, KO-4223 has been shown to inhibit the activity of TRIOBP and to reduce the formation of actin filaments. This suggests that KO-4223 may be an effective drug against various diseases that are characterized by the excessive activation of

Protein Name: TRIO And F-actin Binding Protein

Functions: May regulate actin cytoskeletal organization, cell spreading and cell contraction by directly binding and stabilizing filamentous F-actin. The localized formation of TARA and TRIO complexes coordinates the amount of F-actin present in stress fibers. May also serve as a linker protein to recruit proteins required for F-actin formation and turnover

More Common Targets